Vicriviroc (SCH 417690) Treatment Protocol in HIV-Infected Subjects: A Rollover Study for ACTG Protocol A5211 (Protocol No. P04100).

Trial Profile

Vicriviroc (SCH 417690) Treatment Protocol in HIV-Infected Subjects: A Rollover Study for ACTG Protocol A5211 (Protocol No. P04100).

Completed
Phase of Trial: Phase II

Latest Information Update: 14 May 2014

At a glance

  • Drugs Vicriviroc (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Schering-Plough
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Nov 2010 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
    • 18 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top